Green Thumb Industries Inc. (CNSX: GTII)
Health Care · Pharmaceuticals · US
CA$10.55
+2.73% today · -8.8% 1Y
Green Thumb Industries Inc. (CNSX: GTII) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.67B and employs 5,000 people.
Over the last twelve months the share price has lost 8.8%, trading between 7.40 and 14.39.
Tweenvest scores Green Thumb Industries Inc. across four factors: quality 66/100, value 68/100, growth 73/100. Its strongest factor is growth.
GTII price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.67B
- Revenue (TTM)
- $1.21B
- P/E
- 13.41
- EPS
- 0.55
- Dividend yield
- —
- Beta (5Y)
- 0.92
- 52-week high
- CA$14.39
- 52-week low
- CA$7.40
- Avg volume (3M)
- —
- Shares outstanding
- 218.59M
- Employees
- 5,000
- Next earnings
- —
About Green Thumb Industries Inc.
Green Thumb Industries Inc. is a U.S.-based company focused on the cultivation, processing, and distribution of cannabis products for both medicinal and adult recreational consumption. Its diverse product portfolio includes raw cannabis flower and a wide array of manufactured and pre-packaged offerings such as pre-rolls, concentrates, vaporizers, tinctures, edibles, and topicals. These are marketed under well-known brand names including Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM. The company employs a dual distribution strategy, supplying its products primarily to third-party retail outlets while also engaging in direct-to-consumer sales through its owned and operated dispensaries. As of April 11, 2022, GTI operated a network of 77 retail stores across the United States. Established in 2014, the firm maintains its corporate headquarters in Chicago, Illinois.
- ISIN
- CA39342L1085
- Founded
- 2014
- Listed since
- Oct 28, 2003
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.